Infigratinib-话题@MedSci

#Infigratinib#

5篇内容 | 891人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2238181, encodeId=7651223818105, content=<a href='/topic/show?id=4c14935467e' target=_blank style='color:#2F92EE;'>#软骨发育不全#</a> <a href='/topic/show?id=96c3984438' target=_blank style='color:#2F92EE;'>#Infigratinib#</a>, objectTitle=NEJM：口服Infigratinib治疗软骨发育不全儿童的疗效与安全性研究, objectType=article, longId=851914, objectId=bcb985191467, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240627/1719494105549_2570354.jpg, objectUrl=/article/show_article.do?id=bcb985191467, replyNumber=0, likeNumber=0, createdTime=2024-11-21, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=bcb985191467, moduleTitle=NEJM：口服Infigratinib治疗软骨发育不全儿童的疗效与安全性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bcb985191467)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1928046, encodeId=e8e0192804622, content=<a href='/topic/show?id=96c3984438' target=_blank style='color:#2F92EE;'>#Infigratinib#</a>, objectTitle=Clin Cancer Res：FGFR抑制剂Infigratinib单药治疗携带EGFR变异的复发性胶质瘤的疗效, objectType=article, longId=723401, objectId=df51e23401fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df51e23401fa, replyNumber=0, likeNumber=85, createdTime=2023-03-17, rootId=0, userName=oliver169, userId=4fd6156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df51e23401fa, moduleTitle=Clin Cancer Res：FGFR抑制剂Infigratinib单药治疗携带EGFR变异的复发性胶质瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df51e23401fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1928045, encodeId=be2d1928045fe, content=<a href='/topic/show?id=96c3984438' target=_blank style='color:#2F92EE;'>#Infigratinib#</a>, objectTitle=infigratinib国内处方：对肝内胆管癌患者治疗如何？, objectType=article, longId=302059, objectId=1f78302059ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f78302059ab, replyNumber=0, likeNumber=76, createdTime=2022-08-02, rootId=0, userName=oliver169, userId=4fd6156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f78302059ab, moduleTitle=infigratinib国内处方：对肝内胆管癌患者治疗如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f78302059ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1928044, encodeId=53b5192804459, content=<a href='/topic/show?id=96c3984438' target=_blank style='color:#2F92EE;'>#Infigratinib#</a>, objectTitle=Lancet Gastroenterol Hepatol：Infigratinib在FGFR2融合或重排的晚期胆管癌中的疗效和安全性, objectType=article, longId=215464, objectId=286f215464c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=286f215464c0, replyNumber=0, likeNumber=60, createdTime=2021-11-24, rootId=0, userName=oliver169, userId=4fd6156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=286f215464c0, moduleTitle=Lancet Gastroenterol Hepatol：Infigratinib在FGFR2融合或重排的晚期胆管癌中的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=286f215464c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1928043, encodeId=74fb19280439a, content=<a href='/topic/show?id=96c3984438' target=_blank style='color:#2F92EE;'>#Infigratinib#</a>, objectTitle=Eur Urol：继发于选择性成纤维细胞生长因子受体1-3抑制剂Infigratinib（BGJ398）的高磷血症与成纤维细胞生长因子受体3变异的晚期/转移性尿路癌的抗肿瘤疗效有关 , objectType=article, longId=200106, objectId=c2aa200106d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2aa200106d4, replyNumber=0, likeNumber=65, createdTime=2021-06-20, rootId=0, userName=oliver169, userId=4fd6156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2aa200106d4, moduleTitle=Eur Urol：继发于选择性成纤维细胞生长因子受体1-3抑制剂Infigratinib（BGJ398）的高磷血症与成纤维细胞生长因子受体3变异的晚期/转移性尿路癌的抗肿瘤疗效有关 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2aa200106d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1928042, encodeId=eaa4192804286, content=<a href='/topic/show?id=96c3984438' target=_blank style='color:#2F92EE;'>#Infigratinib#</a>, objectTitle=2018年欧洲肿瘤内科学会：Infigratinib在胆管癌中的全新结果, objectType=article, longId=151519, objectId=abe5151519ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=abe5151519ba, replyNumber=0, likeNumber=75, createdTime=2019-01-28, rootId=0, userName=oliver169, userId=4fd6156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=abe5151519ba, moduleTitle=2018年欧洲肿瘤内科学会：Infigratinib在胆管癌中的全新结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=abe5151519ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Infigratinib

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#软骨发育不全# #Infigratinib#

NEJM：口服Infigratinib治疗软骨发育不全儿童的疗效与安全性研究

2024-11-21发表于陕西省

oliver169 (审核中...)

前往app查看评论内容

#Infigratinib#

Clin Cancer Res：FGFR抑制剂Infigratinib单药治疗携带EGFR变异的复发性胶质瘤的疗效

2023-03-17

oliver169 (审核中...)

前往app查看评论内容

#Infigratinib#

infigratinib国内处方：对肝内胆管癌患者治疗如何？

2022-08-02

oliver169 (审核中...)

前往app查看评论内容

#Infigratinib#

Lancet Gastroenterol Hepatol：Infigratinib在FGFR2融合或重排的晚期胆管癌中的疗效和安全性

2021-11-24

oliver169 (审核中...)

前往app查看评论内容

#Infigratinib#

Eur Urol：继发于选择性成纤维细胞生长因子受体1-3抑制剂Infigratinib（BGJ398）的高磷血症与成纤维细胞生长因子受体3变异的晚期/转移性尿路癌的抗肿瘤疗效有关

2021-06-20

oliver169 (审核中...)

前往app查看评论内容

#Infigratinib#

2018年欧洲肿瘤内科学会：Infigratinib在胆管癌中的全新结果

2019-01-28

科室
- - 订阅+
  - 更多科室
工具
服务